LQDA - Liquidia Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.38
+0.03 (+0.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.35
Open8.36
Bid0.00 x 900
Ask0.00 x 1000
Day's Range8.36 - 8.56
52 Week Range8.01 - 38.46
Volume24,167
Avg. Volume102,687
Market Cap156.224M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.25
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019

    Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 (single capsule, 1-2 breaths) correlates with the 54 mcg dose of Tyvaso® (9 breaths), the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavailability and pharmacokinetics (PK) of single doses of LIQ861 and Tyvaso in 18 PAH patients. The company targets NDA submission in late 2019 that will include additional data generated from ongoing development activities.

  • GlobeNewswire23 days ago

    Liquidia to Present at Jefferies Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., June 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, announced that Neal.

  • GlobeNewswirelast month

    Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO). Dr. Katz joins Liquidia with more than 20 years of experience in healthcare finance and corporate development. Most recently, he served as CFO at Argos Therapeutics.

  • GlobeNewswirelast month

    Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced that Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division, Professor of Medicine at Tufts University School of Medicine, and INSPIRE Principal Investigator, will present a poster highlighting data from Liquidia’s Phase 3 INSPIRE trial of LIQ861 for the treatment of pulmonary arterial hypertension (PAH) at the ATS International Conference in Dallas, Texas. The poster will include data on tolerability of LIQ861 and selected exploratory endpoints at two months of treatment, split by New York Heart Association Functional Class.

  • GlobeNewswire2 months ago

    Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating Pulmonary Arterial HypertensionOn Track for Planned New Drug Application (NDA) Submission for LIQ861 in.

  • GlobeNewswire2 months ago

    Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019

    RESEARCH TRIANGLE PARK, N.C., April 23, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire3 months ago

    Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed safety and exploratory endpoint findings at the two-month timepoint for the Phase 3 INSPIRE trial. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, presented the data at the opening plenary session of the 39th International Society for Heart & Lung Transplantation (ISHLT) Meeting and Scientific Sessions in Orlando, Florida. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using its PRINT® Technology, as an alternative to current inhaled treprostinil therapy for the treatment of patients with pulmonary arterial hypertension (PAH) (WHO Group 1).

  • GlobeNewswire3 months ago

    Liquidia Technologies to Present at Needham Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., April 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire3 months ago

    Liquidia Technologies Announces Closing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire3 months ago

    Liquidia Technologies Announces Pricing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 21, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Morrisville company looks to Wall Street — again
    American City Business Journals3 months ago

    Morrisville company looks to Wall Street — again

    Less than a year after its IPO, this Morrisville company wants to raise more cash to fund its core competencies.

  • GlobeNewswire3 months ago

    Liquidia Technologies Announces Proposed Offering of Common Stock

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire4 months ago

    Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line results of its pivotal Phase 3 INSPIRE study in patients with pulmonary arterial hypertension (“PAH”) treated with LIQ861, the first inhaled dry powder formulation of treprostinil. Initial analysis indicates the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, stated: “The top-line analysis of LIQ861 from the INSPIRE study is highly encouraging for physicians and patients.

  • GlobeNewswire4 months ago

    Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trialAccepted by FDA into Emerging Technology Program to support review of PRINT®.

  • GlobeNewswire4 months ago

    Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019

    RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire6 months ago

    Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today reported positive interim safety data from its open-label, multicenter Phase 3 clinical trial (INSPIRE) evaluating LIQ861, an inhaled dry powder formulation of treprostinil, for the treatment of pulmonary arterial hypertension (“PAH”). Patients adding LIQ861 to current non-prostacyclin oral therapies started at a dose of approximately 25 mcg and those transitioned from nebulizer-delivered treprostinil at a stable dose were initiated at a dose of LIQ861 lower than their current stable treprostinil dose.

  • GlobeNewswire7 months ago

    Liquidia Technologies Provides Leadership Update

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that Kevin Gordon, President and Chief Financial Officer, plans to retire from his current role at Liquidia to focus on board and other advisory work. Liquidia has initiated a search process for a new CFO and Mr. Gordon has agreed to continue his employment with the company until March 1, 2019 to support a smooth transition. “On behalf of Liquidia’s employees and Board of Directors, I want to thank Kevin for his many contributions and wish him the best in his next chapter,” stated Neal Fowler, Chief Executive Officer of Liquidia.

  • Liquidia Technologies Inc (NASDAQ:LQDA): Time For A Financial Health Check
    Simply Wall St.7 months ago

    Liquidia Technologies Inc (NASDAQ:LQDA): Time For A Financial Health Check

    Liquidia Technologies Inc (NASDAQ:LQDA) is a small-cap stock with a market capitalization of US$309m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • GlobeNewswire7 months ago

    Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire7 months ago

    Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting

    RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire7 months ago

    Analysis: Positioning to Benefit within Harvest Capital Credit, Zynga, Unique Fabricating, SJW Group, Liquidia Technologies, and Rave Restaurant Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Liquidia Technologies to Present at Jefferies London Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Liquidia Technologies refocuses efforts
    American City Business Journals8 months ago

    Liquidia Technologies refocuses efforts

    Following its initial public offering this summer, Liquidia Technologies is buckling down in preparation for its new drug application next year.

  • GlobeNewswire8 months ago

    Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen.